<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Urologiia</journal-id><journal-title-group><journal-title xml:lang="en">Urologiia</journal-title><trans-title-group xml:lang="ru"><trans-title>Урология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1728-2985</issn><issn publication-format="electronic">2414-9020</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">296467</article-id><article-id pub-id-type="doi">10.18565/urology.2019.1.105-112</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Methanaphylaxis of urolithiasis. Part 3. The factors associated with increase in incidence of urinary stone disease. Current views on the mechanisms of stone formation</article-title><trans-title-group xml:lang="ru"><trans-title>Метафилактика мочекаменной болезни. Часть 3. Факторы роста заболеваемости МКБ. Современный взгляд на механизмы камнеобразования</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Saenko</surname><given-names>V. S</given-names></name><name xml:lang="ru"><surname>Саенко</surname><given-names>В. С</given-names></name></name-alternatives><bio xml:lang="en"><p>MD, professor at the Department of Urology</p></bio><bio xml:lang="ru"><p>д.м.н., профессор кафедры урологии</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Gazimiev</surname><given-names>M. A</given-names></name><name xml:lang="ru"><surname>Газимиев</surname><given-names>М. А</given-names></name></name-alternatives><bio xml:lang="en"><p>MD, professor, of Urology and Male Reproductive Health named after R.M. Fronstein</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, институт урологии и репродуктивного здоровья человека</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pesegov</surname><given-names>S. V</given-names></name><name xml:lang="ru"><surname>Песегов</surname><given-names>С. В</given-names></name></name-alternatives><bio xml:lang="en"><p>Ph.D., urologist at the Department of Extracorporeal Shock-wave lithotripsy of UKB №2</p></bio><bio xml:lang="ru"><p>к.м.н., врач-уролог УКБ № 2</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Alyaev</surname><given-names>Yu. G</given-names></name><name xml:lang="ru"><surname>Аляев</surname><given-names>Ю. Г</given-names></name></name-alternatives><bio xml:lang="en"><p>corresponding member ofRAS, Dr.Med.Sci., professor</p></bio><bio xml:lang="ru"><p>член-корр. РАН, д.м.н., профессор</p></bio><email>ugalayev@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">FGAOU VO of I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2019-02-15" publication-format="electronic"><day>15</day><month>02</month><year>2019</year></pub-date><issue>1</issue><issue-title xml:lang="en">NO1 (2019)</issue-title><issue-title xml:lang="ru">№1 (2019)</issue-title><fpage>105</fpage><lpage>112</lpage><history><date date-type="received" iso-8601-date="2023-02-27"><day>27</day><month>02</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2019, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2019, ООО «Бионика Медиа»</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/1728-2985/article/view/296467">https://journals.eco-vector.com/1728-2985/article/view/296467</self-uri><abstract xml:lang="en"><p>All theories of stone formation are based on the common condition, which is the supersaturation ofstone-forming elements. The microelements involved in the stone formation, the most common metabolic disorders and their role in stone formation are discussed.</p></abstract><trans-abstract xml:lang="ru"><p>Все теории камнеобразования объединены основным условием - наличием пересыщения мочи камнеобразующими минералами. В представленном материале обсуждены микроэлементы, участвующие в формировании мочевых камней, наиболее часто встречающиеся метаболические нарушения и их роль в камнеобразовании.</p></trans-abstract><kwd-group xml:lang="en"><kwd>urinary stone disease</kwd><kwd>urolithiasis</kwd><kwd>theories of stone formation</kwd><kwd>stone-forming substances</kwd><kwd>metabolic disturbances</kwd><kwd>oxaluria</kwd><kwd>citraturia</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>мочекаменная болезнь</kwd><kwd>уролитиаз</kwd><kwd>теории камнеобразования</kwd><kwd>минералы мочи</kwd><kwd>метаболические нарушения</kwd><kwd>оксалурия</kwd><kwd>цитратурия</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Marshall R.W., Cochran M., Hodgkinson A. Relationships between calcium and oxalic acid intake in the diet and their excretion in the urine of normal and renal-stone-forming subjects. Clin Sci. 1972;43:91-99.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Massey L.K., Roman-Smith H., Sutton R.A. Effect of dietary oxalate and calcium on urinary oxalate and risk of formation of calcium oxalate kidney stones. J. Am Diet Assoc 1993;93:901-906.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Ntuhaus T.J., Belzer T., Blau N., Hoppe B., Sidhu H., Leumann E. Urinary oxalate excretion in urolithiasis and nephrocalcinosis. Arch Dis Child. 2000;82:322-326.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Zlatopol’sky E. The physiology and pathophysiology of calcium, magnesium and phosphorus metabolism: translation from English. (pod redaktsiey S/ Klara). М.: Medicina, 1987, p. 217-278. Кгыышфт (Златопольски Э. Патофизиология обмена кальция, магния и фосфора. Почки и гомеостаз в норме и патологии: пер с англ. (под редакцией С. Клара). М.: Медицина, 1987. С. 217-278).</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Marangella M., Fruttero B., Bruno M., Linari F. Hyperoxaluria in idiopathic calcium stone disease: further evidence of intestinal hyperabsorption of oxalate. Clin Sri. 1982;63:381-385.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Bushinsky D.A.,Bashir M.A.,Riordon D.R.,Nakagawa Y., Coe F.L., Grynpas M.D. Increased dietary oxalate does not increase urinary calcium oxalate saturation in hypercalciuric rats. Kidney Int. 1999;55:602-612.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Shiri R., Koskimaki J., Hakkinen J. Tampere Ageing Male Urological Study. Effects of age, comorbidity and lifestyle factors on erectile function: Tampere Ageing Male Urological Study (TAMUS). Eur. Urol. 2004;45:628-633.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>DeMaria E.J. Bariatric surgery for morbid obesity. N. Engl J. Med. 2007;356:2176-2183.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Аполихин О.И., Сивков А.В., Константинова О.В., Селькова Е.П., Затевалов А.М., Ручкина И.Н., Гецаев Т.К. Сравнительная оценка содержания летучих жирных кислот в толстой кишке у пациентов с мочекаменной болезнью и больных уролитиазом с сопутствующим синдромом раздраженного кишечника. Тезисы докл. VIII Всероссийская научно-практическая конференция с международным участием «Рациональная фармакотерапия в урологии». 13-14 февраля 2014. С. 14-15</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Nelson W.K., Houghton S.G., Milliner D.S., Lieske J.C., Sarr M.G. Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass. Surg Obes Relat Dis 2005;1:481-485.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Asplin J.R., Coe F.L. Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. J. Urol. 2007;177:565-569.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Jääskeläinen T., Ilconen S.T., Lundgvist, Erkkola at al. The positive impact of general vitamin D. food fortification policy on vitamin D. status in a representative adult Finish population: evidence from an 11-y followup based on standardized 25-hydroxyvitamin D. data. Am.J. Clin Nutr. 2017;105(6):1512-1520. Doi: 10.3945/ajcn.116.151415.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Allison M.J., Dawson K.A., Mayberry W.R., Foss J.G. Oxalobacter formigenes gen.nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol. 1985;141:1-7.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Kwak С. et al. Urinary Oxalate level and the Enteric Bacterium Oxalobacter formingenes in Patients with Calcium Oxalate Urolithiasis. Eur. Urol. 2003;44:475-481.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Sidhu H.L., Enatska L., Ogden S., Williams W.N., Allison M.J., Peck A.B. Evaluating children in the Ukraine for colonization with the intestinal bacterium Oxalobacter formingenes, using a polymerase chain reacton detection system. Mol Diagn. 1997;2:89-97.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Miller A.W., Dearing D. The metabolic and ecological interactions of oxalate-degrading bacteria in the mammalian gut. Pathogens. 2013;2:636-652. Doi: 10.3390/pathogens2040636.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Azcarate-Peril M.A., Bruno-Barcena J.M., Hassan H.M., Klaenhammer T.R. Transcriptional and functional analysis of oxalyl-coenzyme A (CoA) decarboxylase and formyl-CoA transferase genes from lactobacillus acidophilus. Appl Environ Microbiol. 2006;72:1891-1899. Doi: 10.1128/ AEM.72.3.1891-1899.2006.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Arvans D., Jung Y.C., Antonopoulos D., Koval J., Granja I., Bashir M., Karrar E., Roy-Chowdhury J., Musch M., Asplin J. et al. Oxalobacter formigenes-derived bioactive factors stimulate oxalate transport by intestinal epithelial cells. J. Am Soc Nephrol. 2017;28:876-887. Doi: 10.1681/ASN.2016020132.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Lange J.N., Wood K.D., Wong H., Otto R., Muffarrij P.W., Knight J., Akpinar H., Holmes R.P., Assimos D.G. Sensitivity of human strains of Oxalobacter formingenes to commonly prescribed antibiotics. Urol. 2012;79(6):1286-1289.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Jiang J., Knight J., Neiberg R., Holmes R.P., Assimos D.G. Impact of dietary calcium and oxalate , and oxalobacter formigenes colonization on urinary oxalate excretion. J. Urol. 2011;186(1):135-139.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Borsatti A. Calcium oxalate nephrolithiasis: defective oxalate transport. Kidney Int 1991;39:1283-1298.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Mehta M., Goldfarb D.S., Nazzal L. The role of the microbiome in kidney stone formation. Int J. Surg. 2016;36 (PtD):607-612. Doi: 10.1016/j. ijsu.2016.11.024.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Константинова О.В., Яненко Э.К., Перепанова Т.С., Голованов С.А., Степанчук Ю.Ю. состояние обмена камнеобразующих веществ у больных уролитиазом при применении эубиотика на основе оксалатдеградирующих лактобацилл. Тезисы докл. V. Всероссийская конференция по фармакологии почек и водно-солевого обмена. Чебоксары, 1997</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Miller A.W., Dale C., Dearingb M.D. The Induction of Oxalate Metabolism In Vivo Is More Effective with Functional Microbial Communities than with Functional Microbial Species.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Menghan Liu, Hyunwook Koh, Zachary D. Kurtz, Thomas Battaglia, Amanda PeBenito, Huilin Li, Lama Nazzal. Oxalobacter formigenes-associated host features and microbial community structures examined using the American Gut Project Microbiome. 2017;5:108. Doi: 10.1186/s40168-017-0316-0 PMCID: PMC5571629.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Журнал Химия и жизнь. 1994;1</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Пытель Ю.А. Золотарев И.И. Уратный нефролитиаз. 1995. C. 23-24</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Emmerson B.T., Gordon R.B., Johnson L.A. Urate Kinetics in Hypoxanthi-ne - guanine Phosphoribosyltransferase Deficiency: Their Significance for the Understanding of Gout. Quart. J. Med. 1976;45:49-61.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Sundy J.S., Becker M.A., Baraf H.S. et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment - failure gout: results of a phase II randomized study. Arthritis Rheum. 2008;58:2882-2891.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Chen C.J., Shi Y., Hearn A. et al. My D88-dependent Il-1 receptors signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J. Clin Invest. 2006;116:2262-2271.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Horl W.H. Uremic toxins: new aspects. J. Nephrol. 2000;13(Suppl 3): S83-S88.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Dadon M., Frochot V. Crystalluria. Clinical chemistry and laboratory medicine 2015;53(suppl 2):s1479-1487.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Sakhaee K. et al. Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts. Kidney Int. 1983;24(3):348-352.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Pak C.Y., et al. Biochemical profile of stone-forming patients with diabetes mellitus. Urology. 2003;61(3):523-572.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Ekaratanawong S., et al. Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. J. Pharmacol Sci. 2004;94(3):297-304.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Lieske J. C. et al. Diabetes mellitus and the risk of urinary tract stones: a population-based case-control study. Am J. Kidney Dis. 2006;48(6):897-904.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Abate N. et al. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004;65(2):386-392.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Maalouf N.M., et al. Metabolic basis for low urine pH in type 2 diabetes. Clin J. Am Soc Nephrol. 2010;5(7):1277-1281.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Johnson C.D., Mole D.R., Pestridge A. Postprandial alkaline tide: does it exist? Digestion 1995;56(100-106):54. 40. ßilobrov V.M., Chugaj A.V., Bessarabov V.I. Urine pH variation dynamics inhealthy individuals and calculus formers. Urol Int 1990;45:326- 331.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Allen L., Oddoye A., Margen S. Protein-inducedhypercalciuria: a longer term study. Rev Urol.2009;11(3):134-144.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Grases F., March J.G., Prieto R.M., Simonet B.M., Costa-Bauza A., Garci'a-Raja A., Conte A. Urinary phytate in calcium oxalate stone formers and healthy people-dietary effects on phytate excretion. Scand J. Urol Nephrol 2000;34:162-164.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Gray R.W., Wilz D.R., Caldas A.E., Lemann J. The importance ofphosphate in regulating plasma 1,25-(OH)2-vitamin D. levels in humans: Studies in healthy subjects in calcium-stone formers and in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 1977;45:299-306.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Caldas A.E., Gray R.W., Lemann J. The simultaneous measurement of vitamin D. metabolites in plasma: Studies in healthy adults and in patients with calcium nephrolithiasis. J. Lab. Clin. Med. 1978;91:840-849.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Tang J., Chonchol M.B. Vitamin D. and kidney stone disease. Curr Opin Nephrol Hypertens. 2013;22(4):383-89. Doi: 10.1097/MNH.0b013e328360bbcd.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Haghighi A., Samimagham H., Gohardehi G. Calcium and vitamin D. supplementation and risk of kidney stone formation in postmenopausal women. Iran J. Kidney Dis. 2013;7(3):210-213.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Domrongkitchaiporn S., Ongphiphadhanakul B., Stitchantrakul W., Piaseu N., Chansirikam S., Puavilai G., Rajatanavin R. Risk of calcium oxalate nephrolithiasis after calcium or combined calcium and calcitriol supplementation in postmenopausal women. Osteoporos Int. 2000;11(6):486-492.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Nguyen S., Baggerly L., French C., Heaney R.P., Gorham E.D., Garland C.F. 25-Hydroxyvitamin D. in the range of 20 to 100 ng/mL and incidence of kidney stones. Am J. Public Health. 2014;104(9):1783-87. Doi: 10.2105/ AJPH.2013.301368.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Henglong Hu, Jiaqiao Zhang, Yuchao Lu, Zongbiao Zhang, Baolong Qin, Hongbin Gao, Yufeng Wang, Jianning Zhu, Qing Wang, Yunpeng Zhu, Yang Xun and Shaogang Wang. Association between Circulating Vitamin D. Level and Urolithiasis: A Systematic Review and Meta-Analysis. Nutrients. 2017;9:301. Doi:10.3390/nu9030301.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Iida K., Shinki T., Yamaguchi A., DeLuca H.F., Kurokawa K., Suda T. A possible role of vitamin D. receptors in regulating vitamin D. activation in the kidney. Proc NatlAcad Sci U. S. A. 1995;92(13):6112-6116.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Константинова О.В. Прогнозирование и принципы профилактики мочекаменной болезни. Автореф. дисс. д.м.н., М., 1999. С. 39</mixed-citation></ref></ref-list></back></article>
